[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Investigation Report on China Octreotide Market, 2010-2019

June 2015 | 30 pages | ID: ICC019664B3EN
China Research and Intelligence Co., Ltd.

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Description

Octreotide, an octapeptide that mimics natural somatostatin, has been widely used in clinic for the treatment of upper gastrointestinal variceal hemorrhage and stomach ulcer bleeding, acute pancreatitis, endocrine tumors.

First approved to be sold in 1996, octreotide was developed by Novartis AG under the trade name of Sandostatin. The approved indications at that time were acromegaly, diarrhea and pancreatic cancer. Due to its sure efficacy and various indications, octreotide has become one of the most highly stressed biosimilar compounds. Octreotide has remained a steady growth ever since its listing and its sales value surpassed USD 1000 million in 2007. Sandostatin’s US patent expired in Jun. 2014. Although the generic drug of octreotide made by Sun Pharmaceutical Industries Ltd got FDA’s approval in 2008, Novartis’s octreotide still brought in sales revenue of USD 1589 million in 2013.

After Octreotide made by Novartis entered China in 2004, many local generic drugs came into the market successively. Octreotide has undergone a fast development in China with annual sales value rising from CNY 100 million in 2005 to CNY 466 million in 2014 and CAGR reaching up to 15.8% during the period of 2005-2014. Octreotide enjoys a vast demand in China. Novartis AG (Sweden), Chengdu Tiantaishan Pharmaceutical Co., Ltd, Sinopharm A-THINK Pharmaceutical Co., Ltd, Peking Sunho Pharmaceutical Co., Ltd and Shanghai No.1 Biochemical & Pharmaceutical Co., Ltd all take up certain shares in the Chinese market, among which Novartis AG (Sweden) has the largest market share of over 70%, sales value in 2014 reaching up to CNY 334 million in 2014.

The market size of octreotide in China is expected to keep growing in the next few years.

Readers can get at least the following information from this report:
  • market size of octreotide in China
  • market share of manufacturers of octreotide in China
  • price of octreotide in Chinese market
  • major manufacturers of octreotide in Chinese market
  • market outlook of octreotide in China
  • The author suggests the following groups of people purchase this report:
    • manufacturers of drugs for endocrine and metabolic regulation
    • investors/ research institutions interested in Chinese medicine market
    • any interest in the Chinese medicine market, please contact CRI for customized survey service
1 RELATED CONCEPTS OF OCTREOTIDE

1.1 Indication
1.2 Sales Status in Global Market

2 MARKET PROFILE OF OCTREOTIDE IN CHINA

2.1 Patent and Approval Status of Octreotide in China
2.2 Major Manufacturers
2.3 Market Size

3 SURVEY ON SALES STATUS OF OCTREOTIDE IN CHINA, 2010-2014

3.1 Sales Value
  3.1.1 Overall Sales Value
  3.1.2 Sales Value by Regions
3.2 Sales Volume
  3.2.1 Overall Sales Volume
  3.2.2 Sales Volume by Regions

4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURERS OF OCTREOTIDE IN CHINA, 2010-2014

4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 SURVEY ON DOSAGE FORMS OF OCTREOTIDE IN CHINA, 2010-2014

5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume

6 REFERENCE PRICE OF OCTREOTIDE IN CHINESE HOSPITALS IN 2014

6.1 Sandoz GmbH (AT) (Trade Name: Sandostatin LAR)
6.2 Shanghai No.1 Biochemical & Pharmaceutical Co., Ltd
6.3 Wellso Pharmaceutical Co., Ltd
6.4 Peking Sunho Pharmaceutical Co., Ltd
6.5 Sinopharm A-THINK Pharmaceutical Co., Ltd
6.6 GeneScience Pharmaceuticals Co., Ltd
6.7 Chengdu Tiantaishan Pharmaceutical Co., Ltd
6.8 Novartis AG (Sweden) (Trade Name: Sandostatin LAR)

7 MAJOR MANUFACTURERS OF OCTREOTIDE IN CHINESE MARKET, 2010-2014

7.1 Novartis AG (Switzerland)
7.2 Chengdu Tiantaishan Pharmaceutical Co., Ltd
7.3 Sinopharm A-THINK Pharmaceutical Co., Ltd
7.4 Peking Sunho Pharmaceutical Co., Ltd
7.5 Shanghai No.1 Biochemical & Pharmaceutical Co., Ltd

8 MARKET OUTLOOK OF OOCTREOTIDE IN CHINA, 2015-2019

8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape

SELECTED CHARTS

Chart Patent and Approval Status of Octreotide in China
Chart Sales Status of Octreotide in China, 2010-2014
Chart Sales Value of Octreotide in China, 2010-2014
Chart Sales Value of Octreotide in Some Regions in China, 2010-2014
Chart Sales Volume of Octreotide in China, 2010-2014
Chart Market Share of TOP5 Manufacturers of Octreotide for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Octreotide Made by Novartis (Switzerland) in China, 2010-2014
Chart Sales Value and Market Share of Octreotide Made by Sinopharm A-THINK in China, 2010-2014
Chart Sales Value and Market Share of Octreotide Made by Shanghai No.1 Biochemical & Pharmaceutical in China, 2010-2014
Chart Sales Value and Market Share of Octreotide Made by Chengdu Tiantaishan in China, 2010-2014
Chart Sales Value and Market Share of Octreotide Injection in China, 2010-2014
Chart Price of Octreotide Made by Sandoz GmbH (AT) in Some Chinese Cities in 2014
Chart Price of Octreotide Made by Shanghai No.1 Biochemical & Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Octreotide Made by Wellso Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Octreotide Made by Peking Sunho Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Octreotide Made by Sinopharm A-THINK Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Octreotide Made by GeneScience Pharmaceuticals Co., Ltd in Some Chinese Cities in 2014
Chart Price of Octreotide Made by Chengdu Tiantaishan Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Octreotide Made by Novartis AG (Sweden) in Some Chinese Cities in 2014


More Publications